DARBID
LOE ApproachingNDAORALTABLET
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARBID is an oral small-molecule tablet approved by GSK in 1957, representing a legacy therapeutic from the early NDA era. The specific indication and mechanism of action are not publicly detailed in available records, limiting assessment of current clinical relevance. As an oral small molecule with nearly 70 years of market presence, it likely serves a chronic or symptomatic indication with established safety data.
LOE Approaching
With LOE approaching and low competitive pressure (30%), the brand team is likely in defensive mode, focusing on retention and lifecycle management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DARBID presents limited career growth opportunity due to its LOE-approaching lifecycle and absence of linked job postings. Roles available focus on cost management, market defense, and operational excellence rather than innovation or expansion. This is a maintenance assignment, suitable for professionals seeking stability but not career acceleration.
Brand Manager (defensive)
Worked on DARBID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.